The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationRittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Self-citationBean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Gainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30033-x · Cited by 1,183
Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., Yang, J. C.-H., Barrett, J. C., & Jänne, P. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7162 · Cited by 850
Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839
Seto, T., Kato, T., Nishio, M., Goto, K., Atagi, S., Hosomi, Y., Yamamoto, N., Hida, T., Maemondo, M., Nakagawa, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70381-x · Cited by 750
Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718
Goss, G., Tsai, C.-M., Shepherd, F. A., Bazhenova, L., Lee, J. S., Chang, G.-C., Crino, L., Satouchi, M., Chu, Q., Hida, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30508-3 · Cited by 645
Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636
Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0560 · Cited by 583
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Self-citationOsimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Ramalingam, S. S., Yang, J. C.-H., Lee, C. K., Kurata, T., Kim, D.-W., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenkov, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7576 · Cited by 547
Self-citationLee, J.-K., Lee, J., Kim, S., Kim, S., Youk, J., Park, S., An, Y., Keam, B., Kim, D.-W., Heo, D. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9096 · Cited by 505
Murtaza, M., Dawson, S.-J., Pogrebniak, K., Rueda, O. M., Provenzano, E., Grant, J., Chin, S.-F., Tsui, D. W. Y., Marass, F., Gale, D., et al. (2015) · Nature Communications · doi:10.1038/ncomms9760 · Cited by 483
Kelly, K., Altorki, N. K., Eberhardt, W. E. E., O'Brien, M. E. R., Spigel, D. R., Crinò, L., Tsai, C.-M., Kim, J.-H., Cho, E. K., Hoffman, P. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.8918 · Cited by 480
Schuler, M., Wu, Y.-L., Hirsh, V., O’Byrne, K., Yamamoto, N., Mok, T., Popat, S., Sequist, L. V., Massey, D., Zazulina, V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.11.014 · Cited by 361
Goss, G. D., O'Callaghan, C., Lorimer, I., Tsao, M.-S., Masters, G. A., Jett, J., Edelman, M. J., Lilenbaum, R., Choy, H., Khuri, F., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1816 · Cited by 356
Naumov, G. N., Nilsson, M. B., Cascone, T., Briggs, A., Straume, O., Akslen, L. A., Lifshits, E., Byers, L. A., Xu, L., Wu, H.-K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2904 · Cited by 349
Sundaresan, T. K., Sequist, L. V., Heymach, J. V., Riely, G. J., Jänne, P. A., Koch, W. H., Sullivan, J. P., Fox, D. B., Maher, R., Muzikansky, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1031 · Cited by 347
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
Porta, R., Sánchez-Torres, J. M., Paz-Ares, L., Massutí, B., Reguart, N., Mayo, C., Lianes, P., Queralt, C., Guillem, V., Salinas, P., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00195609 · Cited by 316
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Li, Y.-S., Jiang, B.-Y., Yang, J.-J., Tu, H.-Y., Zhou, Q., Guo, W.-B., Yan, H.-H., & Wu, Y.-L. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.029 · Cited by 312
Rosell, R., Molina, M. A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2158 · Cited by 304
Eberlein, C. A., Stetson, D., Markovets, A. A., Al-Kadhimi, K. J., Lai, Z., Fisher, P. R., Meador, C. B., Spitzler, P., Ichihara, E., Ross, S. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3167 · Cited by 301
Haratani, K., Hayashi, H., Tanaka, T., Kaneda, H., Togashi, Y., Sakai, K., Hayashi, K., Tomida, S., Chiba, Y., Yonesaka, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx183 · Cited by 296
Shi, Y. K., Wang, L., Han, B. H., Li, W., Yu, P., Liu, Y. P., Ding, C. M., Song, X., Ma, Z. Y., Ren, X. L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx359 · Cited by 287
Jenkins, S., Yang, J. C.-H., Ramalingam, S. S., Yu, K., Patel, S., Weston, S., Hodge, R., Cantarini, M., Jänne, P. A., Mitsudomi, T., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.003 · Cited by 269
Self-citationAhn, M.-J., Yang, J., Yu, H., Saka, H., Ramalingam, S., Goto, K., Kim, S.-W., Yang, L., Walding, A., & Oxnard, G. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30246-5 · Cited by 234
Self-citationCosta, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229
Self-citationWatanabe, M., Kawaguchi, T., Isa, S.-I., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2151 · Cited by 216
Yu, H. A., Arcila, M. E., Hellmann, M. D., Kris, M. G., Ladanyi, M., & Riely, G. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt573 · Cited by 206
Liao, B.-C., Lee, J.-H., Lin, C.-C., Chen, Y.-F., Chang, C.-H., Ho, C.-C., Shih, J.-Y., Yu, C.-J., & Yang, J. C.-H. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000669 · Cited by 185
Rosell, R., Dafni, U., Felip, E., Curioni-Fontecedro, A., Gautschi, O., Peters, S., Massutí, B., Palmero, R., Aix, S. P., Carcereny, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30129-7 · Cited by 182
Self-citationRemon, J., Caramella, C., Jovelet, C., Lacroix, L., Lawson, A., Smalley, S., Howarth, K., Gale, D., Green, E., Plagnol, V., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx017 · Cited by 168
Self-citationIuchi, T., Shingyoji, M., Itakura, M., Yokoi, S., Moriya, Y., Tamura, H., Yoshida, Y., Ashinuma, H., Kawasaki, K., Hasegawa, Y., et al. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0760-9 · Cited by 165
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
Lin, K., Cheng, J., Yang, T., Li, Y., & Zhu, B. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.030 · Cited by 152
Planchard, D., Brown, K. H., Kim, D.-W., Kim, S.-W., Ohe, Y., Felip, E., Leese, P., Cantarini, M., Vishwanathan, K., Jänne, P. A., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2992-z · Cited by 152
Self-citationKuiper, J. L., Hendriks, L. E. L., van der Wekken, A. J., de Langen, A. J., Bahce, I., Thunnissen, E., Heideman, D. A. M., Berk, Y., Buijs, E. J. M., Speel, E. M., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.05.023 · Cited by 137
Jovelet, C., Ileana, E. E., Deley, M. L., Motté, N., Rosellini, S., Romero, A., Lefèbvre, C., Pedrero, M., Pata-Merci, N., Droin, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2470 · Cited by 136
Remón, J., Menis, J., Hasan, B., Peric, A., Maio, E. D., Novello, S., Reck, M., Berghmans, T., Wasąg, B., Besse, B., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.02.005 · Cited by 110
Yang, J., Ramalingam, S. S., Jänne, P. A., Cantarini, M., & Mitsudomi, T. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30325-2 · Cited by 97
Self-citationIwama, E., Sakai, K., Azuma, K., Harada, T., Harada, D., Nosaki, K., Hotta, K., Ohyanagi, F., Kurata, T., Fukuhara, T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw531 · Cited by 96
Yang, J. C., Kim, D., Kim, S., Cho, B. C., Lee, J.-S., Ye, X., Yin, X., Yang, Z., Jiang, H., & Ahn, M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9002 · Cited by 95
Reguart, N., & Remon, J. (2015) · Future Oncology · doi:10.2217/fon.15.15 · Cited by 91
Update to Rociletinib Data with the RECIST Confirmed Response Rate
Sequist, L. V. D., Soria, J., & Camidge, D. R. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1602688 · Cited by 77
Mok, T. S. K., Ahn, M., Han, J., Kang, J. H., Katakami, N., Kim, H. R., Hodge, R. A., Ghiorghiu, D. C., Cantarini, M., Wu, Y.-L. L. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9005 · Cited by 63
Lü, S., Ding, D., Yu, Y., Li, Z., & Niu, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s58870 · Cited by 48
Park, K., Lee, J.-S., Lee, K. H., Kim, J.-H., Cho, B. C., Min, Y. J., Choi, Y., Han, J., Kim, B.-S., Kim, J.-S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9055 · Cited by 43
Programmed death-ligand 1 expression and T790M status in EGFR -mutant non-small cell lung cancer
Hata, A., Katakami, N., Nanjo, S., Okuda, C., Kaji, R., Masago, K., Fujita, S., Yoshida, H., Zama, K., Imai, Y., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.022 · Cited by 40
Thress, K. S., Markovets, A. A., Barrett, J. C., Chmielecki, J., Goldberg, S. B., Shepherd, F. A., Vowler, S. L., & Oxnard, G. R. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9018 · Cited by 40
Tan, D. S.-W., Yang, J. C., Leighl, N. B., Riely, G. J., Sequist, L. V. D., Felip, E., Seto, T., Wolf, J., Moody, S. E., Adams, K. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9044 · Cited by 39
Self-citationJovelet, C., Madic, J., Remón, J., Honoré, A., Girard, R., Rouleau, É., André, B., Besse, B., Droniou, M., & Lacroix, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183319 · Cited by 35
Yu, H. A., Spira, A. I., Horn, L., Weiss, J. M., West, H., Giaccone, G., Evans, T. L., Kelly, R. J., Desai, B. B., Krivoshik, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9050 · Cited by 29
Ding, D., Yu, Y., Li, Z., Niu, X., & Lu, S. (2014) · Dove Medical Press (Taylor and Francis Group) · Cited by 22
A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
Ofuji, K., Tada, Y., Yoshikawa, T., Shimomura, M., Yoshimura, M., Saito, K., Nakamoto, Y., & Nakatsura, T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2787 · Cited by 21
Mitsudomi, T., Ahn, M.-J., Bazhenova, L. A., Blackhall, F. H., Hida, T., Tarruella, M. M., Vowler, S. L., Laus, G., Janne, P. A., & Yang, J. C.-H. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx380.050 · Cited by 18
Abstract B153: Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291
Vishwanathan, K., Dickinson, P. A., Bui, K., Weilert, D. K., So, K., Thomas, K., Lisbon, E. A., & Plummer, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-b153 · Cited by 10
Zhang, L., Zhao, H., Hu, B., Ji, J., Zheng, X., Zhang, Y., Ma, Y., Ge, J., Zou, B., Fang, X., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw368.03 · Cited by 6
Cited by
Non–Small Cell Lung Cancer, Version 4.2024
Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2204.0023 · Cited by 855
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Metadata
- Authors
- Remon, J., Steuer, C. E., Ramalingam, S. S., & Felip, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 29
- Issue
- suppl_1
- Pages
- i20-i27
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2790465248
- Cited by
- 322
- References
- 73
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.